Skip to main content
Erschienen in: Clinical Pharmacokinetics 6/2015

01.06.2015 | Original Research Article

Nicotine and Cotinine Exposure from Electronic Cigarettes: A Population Approach

verfasst von: Nieves Vélez de Mendizábal, David R. Jones, Andy Jahn, Robert R. Bies, Joshua W. Brown

Erschienen in: Clinical Pharmacokinetics | Ausgabe 6/2015

Einloggen, um Zugang zu erhalten

Abstract

Background and Objectives

Electronic cigarettes (e-cigarettes) are a recent technology that has gained rapid acceptance. Still, little is known about them in terms of safety and effectiveness. A basic question is how effectively they deliver nicotine; however, the literature is surprisingly unclear on this point. Here, a population pharmacokinetic model was developed for nicotine and its major metabolite cotinine with the aim to provide a reliable framework for the simulation of nicotine and cotinine concentrations over time, based solely on inhalation airflow recordings and individual covariates [i.e., weight and breath carbon monoxide (CO) levels].

Methods

This study included ten adults self-identified as heavy smokers (at least one pack of cigarettes per day). Plasma nicotine and cotinine concentrations were measured at regular 10-min intervals for 90 min while human subjects inhaled nicotine vapor from a modified e-cigarette. Airflow measurements were recorded every 200 ms throughout the session. A population pharmacokinetic model for nicotine and cotinine was developed based on previously published pharmacokinetic parameters and the airflow recordings. All of the analyses were performed with the non-linear mixed-effect modeling software NONMEM® version 7.2.

Results

The results show that e-cigarettes deliver nicotine effectively, although the pharmacokinetic profiles are lower than those achieved with regular cigarettes. Our pharmacokinetic model effectively predicts plasma nicotine and cotinine concentrations from the inhalation volume, and initial breath CO.

Conclusion

E-cigarettes are effective at delivering nicotine. This new pharmacokinetic model of e-cigarette usage might be used for pharmacodynamic analysis where the pharmacokinetic profiles are not available.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Yamazaki H, Horiuchi K, Takano R, Nagano T, Shimizu M, Kitajima M, et al. Human blood concentrations of cotinine, a biomonitoring marker for tobacco smoke, extrapolated from nicotine metabolism in rats and humans and physiologically based pharmacokinetic modeling. Int J Environ Res Public Health. 2010;7:3406–21.CrossRefPubMedCentralPubMed Yamazaki H, Horiuchi K, Takano R, Nagano T, Shimizu M, Kitajima M, et al. Human blood concentrations of cotinine, a biomonitoring marker for tobacco smoke, extrapolated from nicotine metabolism in rats and humans and physiologically based pharmacokinetic modeling. Int J Environ Res Public Health. 2010;7:3406–21.CrossRefPubMedCentralPubMed
2.
Zurück zum Zitat Teeguarden JG, Housand CJ, Smith JN, Hinderliter PM, Gunawan R, Timchalk CA. A multi-route model of nicotine–cotinine pharmacokinetics, pharmacodynamics and brain nicotinic acetylcholine receptor binding in humans. Regul Toxicol Pharmacol. 2013;65:12–28.CrossRefPubMed Teeguarden JG, Housand CJ, Smith JN, Hinderliter PM, Gunawan R, Timchalk CA. A multi-route model of nicotine–cotinine pharmacokinetics, pharmacodynamics and brain nicotinic acetylcholine receptor binding in humans. Regul Toxicol Pharmacol. 2013;65:12–28.CrossRefPubMed
3.
Zurück zum Zitat Robinson DE, Balter NJ, Schwartz SL. A physiologically based pharmacokinetic model for nicotine and cotinine in man. J Pharmacokinet Biopharm. 1992;20:591–609.CrossRefPubMed Robinson DE, Balter NJ, Schwartz SL. A physiologically based pharmacokinetic model for nicotine and cotinine in man. J Pharmacokinet Biopharm. 1992;20:591–609.CrossRefPubMed
4.
Zurück zum Zitat Etter JF, Bullen C. Electronic cigarette: users profile, utilization, satisfaction and perceived efficacy. Addiction. 2011;106:2017–28.CrossRefPubMed Etter JF, Bullen C. Electronic cigarette: users profile, utilization, satisfaction and perceived efficacy. Addiction. 2011;106:2017–28.CrossRefPubMed
5.
Zurück zum Zitat Caponnetto P, Campagna D, Cibella F, Morjaria JB, Caruso M, Russo C, et al. EffiCiency and Safety of an eLectronic cigAreTte (ECLAT) as tobacco cigarettes substitute: a prospective 12-month randomized control design study. PLoS One. 2013;8:e66317.CrossRefPubMedCentralPubMed Caponnetto P, Campagna D, Cibella F, Morjaria JB, Caruso M, Russo C, et al. EffiCiency and Safety of an eLectronic cigAreTte (ECLAT) as tobacco cigarettes substitute: a prospective 12-month randomized control design study. PLoS One. 2013;8:e66317.CrossRefPubMedCentralPubMed
8.
Zurück zum Zitat Dawkins L, Corcoran O. Acute electronic cigarette use: nicotine delivery and subjective effects in regular users. Psychopharmacology (Berl). 2014;231:401–7.CrossRef Dawkins L, Corcoran O. Acute electronic cigarette use: nicotine delivery and subjective effects in regular users. Psychopharmacology (Berl). 2014;231:401–7.CrossRef
9.
10.
Zurück zum Zitat Flouris AD, Poulianiti KP, Chorti MS, Jamurtas AZ, Kouretas D, Owolabi EO, et al. Acute effects of electronic and tobacco cigarette smoking on complete blood count. Food Chem Toxicol. 2012;50:3600–3.CrossRefPubMed Flouris AD, Poulianiti KP, Chorti MS, Jamurtas AZ, Kouretas D, Owolabi EO, et al. Acute effects of electronic and tobacco cigarette smoking on complete blood count. Food Chem Toxicol. 2012;50:3600–3.CrossRefPubMed
12.
Zurück zum Zitat Hajek P, Goniewicz ML, Phillips A, Myers SK, West O, McRobbie H. Nicotine intake from electronic cigarettes on initial use and after 4 weeks of regular use. Nicotine Tob Res. Epub 2014 Aug 13. Hajek P, Goniewicz ML, Phillips A, Myers SK, West O, McRobbie H. Nicotine intake from electronic cigarettes on initial use and after 4 weeks of regular use. Nicotine Tob Res. Epub 2014 Aug 13.
13.
Zurück zum Zitat Vansickel AR, Cobb CO, Weaver MF, Eissenberg TE. A clinical laboratory model for evaluating the acute effects of electronic “cigarettes”: nicotine delivery profile and cardiovascular and subjective effects. Cancer Epidemiol Biomarkers Prev. 2010;19:1945–53.CrossRefPubMedCentralPubMed Vansickel AR, Cobb CO, Weaver MF, Eissenberg TE. A clinical laboratory model for evaluating the acute effects of electronic “cigarettes”: nicotine delivery profile and cardiovascular and subjective effects. Cancer Epidemiol Biomarkers Prev. 2010;19:1945–53.CrossRefPubMedCentralPubMed
14.
Zurück zum Zitat Eissenberg T. Electronic nicotine delivery devices: ineffective nicotine delivery and craving suppression after acute administration. Tob Control. 2010;19:87–8.CrossRefPubMedCentralPubMed Eissenberg T. Electronic nicotine delivery devices: ineffective nicotine delivery and craving suppression after acute administration. Tob Control. 2010;19:87–8.CrossRefPubMedCentralPubMed
15.
Zurück zum Zitat Middleton ET, Morice AH. Breath carbon monoxide as an indication of smoking habit. Chest. 2000;117:758–63.CrossRefPubMed Middleton ET, Morice AH. Breath carbon monoxide as an indication of smoking habit. Chest. 2000;117:758–63.CrossRefPubMed
16.
Zurück zum Zitat Hukkanen J, Jacob P III, Benowitz NL. Metabolism and disposition kinetics of nicotine. Pharmacol Rev. 2005;57:79–115.CrossRefPubMed Hukkanen J, Jacob P III, Benowitz NL. Metabolism and disposition kinetics of nicotine. Pharmacol Rev. 2005;57:79–115.CrossRefPubMed
17.
Zurück zum Zitat Armitage AK, Dollery CT, George CF, Houseman TH, Lewis PJ, Turner DM. Absorption and metabolism of nicotine from cigarettes. Br Med J. 1975;4:313–6.CrossRefPubMedCentralPubMed Armitage AK, Dollery CT, George CF, Houseman TH, Lewis PJ, Turner DM. Absorption and metabolism of nicotine from cigarettes. Br Med J. 1975;4:313–6.CrossRefPubMedCentralPubMed
18.
Zurück zum Zitat Beal SL. Ways to fit a PK model with some data below the quantification limit. J Pharmacokinet Pharmacodyn. 2001;28:481–504.CrossRefPubMed Beal SL. Ways to fit a PK model with some data below the quantification limit. J Pharmacokinet Pharmacodyn. 2001;28:481–504.CrossRefPubMed
19.
Zurück zum Zitat Benowitz NL, Porchet H, Jacob P III. Nicotine dependence and tolerance in man: pharmacokinetic and pharmacodynamic investigations. Prog Brain Res. 1989;79:279–87.PubMed Benowitz NL, Porchet H, Jacob P III. Nicotine dependence and tolerance in man: pharmacokinetic and pharmacodynamic investigations. Prog Brain Res. 1989;79:279–87.PubMed
20.
Zurück zum Zitat Ludden TM, Beal SL, Sheiner LB. Comparison of the Akaike Information Criterion, the Schwarz criterion and the F test as guides to model selection. J Pharmacokinet Biopharm. 1994;22:431–45.CrossRefPubMed Ludden TM, Beal SL, Sheiner LB. Comparison of the Akaike Information Criterion, the Schwarz criterion and the F test as guides to model selection. J Pharmacokinet Biopharm. 1994;22:431–45.CrossRefPubMed
21.
Zurück zum Zitat Lindbom L, Ribbing J, Jonsson EN. Perl-speaks-NONMEM (PsN)—a Perl module for NONMEM related programming. Comput Methods Programs Biomed. 2004;75:85–94.CrossRefPubMed Lindbom L, Ribbing J, Jonsson EN. Perl-speaks-NONMEM (PsN)—a Perl module for NONMEM related programming. Comput Methods Programs Biomed. 2004;75:85–94.CrossRefPubMed
22.
Zurück zum Zitat Hooker AC, Staatz CE, Karlsson MO. Conditional weighted residuals (CWRES): a model diagnostic for the FOCE method. Pharm Res. 2007;24:2187–97.CrossRefPubMed Hooker AC, Staatz CE, Karlsson MO. Conditional weighted residuals (CWRES): a model diagnostic for the FOCE method. Pharm Res. 2007;24:2187–97.CrossRefPubMed
23.
Zurück zum Zitat Comets E, Brendel K, Mentre F. Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: the npde add-on package for R. Comput Methods Programs Biomed. 2008;90:154–66.CrossRefPubMed Comets E, Brendel K, Mentre F. Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: the npde add-on package for R. Comput Methods Programs Biomed. 2008;90:154–66.CrossRefPubMed
Metadaten
Titel
Nicotine and Cotinine Exposure from Electronic Cigarettes: A Population Approach
verfasst von
Nieves Vélez de Mendizábal
David R. Jones
Andy Jahn
Robert R. Bies
Joshua W. Brown
Publikationsdatum
01.06.2015
Verlag
Springer International Publishing
Erschienen in
Clinical Pharmacokinetics / Ausgabe 6/2015
Print ISSN: 0312-5963
Elektronische ISSN: 1179-1926
DOI
https://doi.org/10.1007/s40262-014-0221-7

Weitere Artikel der Ausgabe 6/2015

Clinical Pharmacokinetics 6/2015 Zur Ausgabe